PRISM MedDevice Mover Microbot (MBOT) Up ~98% on FDA Approval For Human Clinical Trial
    PRISM MedDevice Mover Microbot (MBOT) Up ~98% on FDA Approval For Human Clinical Trial
    PRISM View

    June 03, 2024 - by Ashlee Vogenthaler

    PRISM MedDevice Mover Microbot (MBOT) Up ~98% on FDA Approval For Human Clinical Trial

    03 June 2024

    New York, June 3, 2024 - PRISM MarketView - The PRISM MedDevice Index company and the developer of the innovative LIBERTY® Endovascular Robotic Surgical System, Microbot Medical (MBOT) has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to proceed with its pivotal human clinical trial under its Investigational Device Exemption (IDE) application for the LIBERTY® system.
    Microbot Medical Inc. - Prism MarketView

    Microbot Medical Inc. - Prism MarketView

    Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minim

    Read More

    Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial

    The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular Robotic Surgical System, which together are expected to support a future 510(k) submissionBRAINTREE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces that it has received the U.S. Food and Drug Administration’s (“FDA”) approval to proceed with its pivotal h

    Read More

    The study will take place in the United States, with the company having already signed a clinical trial service agreement with a leading academic medical center. Additionally, efforts are underway to engage other prominent centers to join the trial.
    Concurrently, the company is finalizing its biocompatibility tests as required by the IDE application.

    “The recent FDA authorization to commence our pivotal clinical study, following the submission of our extensive pre-clinical studies and tests, reinforces our confidence in our innovative technology. It also underscores our commitment to achieving significant milestones as we progress towards potential regulatory clearance and subsequent commercialization in the US and other regions worldwide.”

    Harel Gadot, CEO, President, and Chairman

    About PRISM MarketView:
    Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
    To see this content properly accept cookies.
    Disclaimer:
    PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    Prism MarketView | Stock Market News & Investment Opportunities
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.